Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR-Cas9 IP to Cosmo Bio

NEW YORK — ERS Genomics said on Thursday that it has nonexclusively licensed its CRISPR-Cas9 intellectual property portfolio to Japanese life science research products company Cosmo Bio.

Financial and other terms of the deal were not disclosed.

Dublin-based ERS was founded to provide access to CRISPR-Cas9 patents held by Emmanuelle Charpentier. The IP is shared with Jennifer Doudna and the University of California, as well as with the University of Vienna.

Recent nonexclusive licensees of ERS's IP include Lepton Pharmaceuticals, Cytosurge, and Sumitomo Pharma.

Earlier this year, the US Patent and Trademark Office found that Broad Institute patents covering CRISPR-Cas9 in eukaryotic cells have priority over the IP ERS manages. At the time, ERS said that the USPTO ruling does not impact any of the licenses it has issued to patents not involved in the interference proceedings, including patents covering a variety of CRISPR compositions such as ones with dual-guide and single-guide strand formats.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.